State PBM reform accelerates through 2026, with Theresa Carnegie of Mintz unpacking new laws, rebate pass-through, spread pricing bans, and compliance risks.
|Articles|June 1, 2003
Quality Progress
Author(s)Julie Miller
Finicky travelers seek five-star hotels; avid movie-goers-two thumbs up. And now, healthcare consumers who once thought they'd never have a reliable rating system for hospitals and physicians will be pleased with the progress of the many organizations that now are providing user-friendly quality reports.
Advertisement
Advertisement
Related to this article
Only 19.1% of commercially insured patients with first-episode psychosis were adherent to antipsychotics in the year after starting treatment.
Prioritizing referral completion as much as referral generation will equip organizations to measure results and improve health outcomes.
Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
In this discussion, Chad Hatfield, Pharm.D., M.H.A., BCPS, shares his perspective on the evolving role of pharmacy services and the value of collaboration across health care.
CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Five transcranial magnetic stimulation sessions in one day improved processing speed in adults with schizophrenia, which holds promise for future treatment possibilities, according to researcher Heather Burrell Ward, M.D.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Tariffs on patented drugs now apply to all branded drugmakers
2
A head-to-head phase 3b comparison of bimekizumab with risankizumab in active psoriatic arthritis: Written recap
3
Fewer than 1 in 5 young patients with first-episode psychosis adhere to antipsychotics
4
Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer
5